- Home
- UIS vs DRUG Comparison
UIS vs DRUG Comparison
Compare UIS & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UIS
- DRUG
- Stock Information
- Founded
- UIS 1942
- DRUG 2019
- Country
- UIS United States
- DRUG United States
- Employees
- UIS N/A
- DRUG N/A
- Industry
- UIS EDP Services
- DRUG Pharmaceuticals and Biotechnology
- Sector
- UIS Technology
- DRUG Health Care
- Exchange
- UIS Nasdaq
- DRUG Nasdaq
- Market Cap
- UIS 271.5M
- DRUG 233.2M
- IPO Year
- UIS N/A
- DRUG N/A
- Fundamental
- Price
- UIS $4.73
- DRUG $27.24
- Analyst Decision
- UIS Hold
- DRUG Strong Buy
- Analyst Count
- UIS 1
- DRUG 6
- Target Price
- UIS $6.50
- DRUG $83.25
- AVG Volume (30 Days)
- UIS 735.5K
- DRUG 29.2K
- Earning Date
- UIS 04-30-2025
- DRUG 05-15-2025
- Dividend Yield
- UIS N/A
- DRUG N/A
- EPS Growth
- UIS N/A
- DRUG N/A
- EPS
- UIS N/A
- DRUG N/A
- Revenue
- UIS $1,952,700,000.00
- DRUG N/A
- Revenue This Year
- UIS N/A
- DRUG N/A
- Revenue Next Year
- UIS $3.79
- DRUG N/A
- P/E Ratio
- UIS N/A
- DRUG N/A
- Revenue Growth
- UIS N/A
- DRUG N/A
- 52 Week Low
- UIS $3.32
- DRUG $0.93
- 52 Week High
- UIS $8.93
- DRUG $79.02
- Technical
- Relative Strength Index (RSI)
- UIS 47.92
- DRUG 37.11
- Support Level
- UIS $4.71
- DRUG $25.30
- Resistance Level
- UIS $4.98
- DRUG $31.20
- Average True Range (ATR)
- UIS 0.22
- DRUG 2.36
- MACD
- UIS -0.08
- DRUG -0.48
- Stochastic Oscillator
- UIS 4.64
- DRUG 16.62
About UIS Unisys Corporation New
Unisys Corp is engaged in the provision of technology solutions for clients across the government, financial services, and commercial markets. It operates through three business segments: Digital Workplace Solutions (DWS),Cloud, Applications & Infrastructure Solutions (CA&I), and Enterprise Computing Solutions (ECS). DWS provides workplace solutions featuring intelligent workplace services, proactive experience management and collaboration tools to support business growth. CA&I which provides digital transformation in the areas of cloud migration and management. ECS which provides solutions that harness secure, high-intensity enterprise computing and enable digital services through software-defined operating environments. Majority of revenue is from ECS segment.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.